FDA Signals Potential Expansion of Testosterone Therapy Indication for Low Libido in Men

The U.S. Food and Drug Administration has encouraged sponsors of approved testosterone replacement therapy (TRT) products to engage with the agency if they are interested in pursuing a new indication for treating low libido in men with idiopathic hypogonadism.

The announcement marks an initial regulatory step rather than a formal approval. The FDA said it has reviewed emerging clinical evidence and discussions from a December 2025 expert panel, which suggested TRT may be safe and effective for certain men experiencing low libido linked to low testosterone without an identifiable cause.

Currently, TRT products are only approved for hypogonadism linked to known structural or genetic conditions. The potential expansion would therefore broaden the eligible patient population significantly, subject to future evidence submissions and regulatory review.

FDA Commissioner Marty Makary said emerging data suggests an opportunity to address symptoms affecting quality of life, while emphasising that any new indication would require substantial evidence of safety and effectiveness. Brian J. Christine, Assistant Secretary for Health, also highlighted sexual health as a key component of overall wellbeing, noting the importance of continued clinical research in this area.

For industry stakeholders, the agency has invited holders of approved TRT new drug applications to contact the FDA for guidance on submitting supplemental applications, including required supporting data, by April 30.

While no approval has been granted, the move signals a potential shift in regulatory openness toward expanding TRT’s clinical use in men’s sexual health.